Prevention and cure: The major unmet needs in the management of rheumatoid arthritis.

[1]  G. Simons,et al.  I Would Never Take Preventive Medication! Perspectives and Information Needs of People Who Underwent Predictive Tests for Rheumatoid Arthritis , 2020, Arthritis care & research.

[2]  P. Emery,et al.  How Are Rheumatologists Managing Anticyclic Citrullinated Peptide Antibodies–positive Patients Who Do Not Have Arthritis? , 2019, The Journal of Rheumatology.

[3]  G. Cavalli,et al.  Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis , 2019, Expert review of clinical immunology.

[4]  J. Smolen,et al.  Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis , 2019, Annals of the rheumatic diseases.

[5]  J. Smolen,et al.  Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets , 2019, Nature Reviews Rheumatology.

[6]  P. Emery,et al.  Defining remission in rheumatoid arthritis: does it matter to the patient? A comparison of multi-dimensional remission criteria and patient reported outcomes. , 2019, Rheumatology.

[7]  R. Toes,et al.  Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status , 2019, Annals of the rheumatic diseases.

[8]  A. Iagnocco,et al.  Imaging in the preclinical phases of rheumatoid arthritis. , 2019, Clinical and experimental rheumatology.

[9]  D. Aletaha,et al.  Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. , 2019, Rheumatology.

[10]  P. Emery,et al.  The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis , 2019, Arthritis Research & Therapy.

[11]  D. Courvoisier,et al.  Periodontal status correlates with anti-citrullinated protein antibodies in first-degree relatives of individuals with rheumatoid arthritis. , 2019, Journal of clinical periodontology.

[12]  J. Smolen,et al.  Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis. , 2019, Rheumatology.

[13]  G. Shaddick,et al.  Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor–treated rheumatoid arthritis patients , 2019, Rheumatology.

[14]  P. Emery,et al.  Prevalence of Periodontal Disease and Periodontopathic Bacteria in Anti–Cyclic Citrullinated Protein Antibody–Positive At-Risk Adults Without Arthritis , 2019, JAMA network open.

[15]  A. Giovagnoni,et al.  Ultrasound imaging in rheumatoid arthritis , 2019, La radiologia medica.

[16]  C. Gabay,et al.  Prevotella copri in individuals at risk for rheumatoid arthritis , 2019, Annals of the rheumatic diseases.

[17]  J. Smolen,et al.  Achieving Clinical Remission for Patients With Rheumatoid Arthritis. , 2019, JAMA.

[18]  P. Geborek,et al.  Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a Nationwide Study in Sweden , 2019, Rheumatology.

[19]  B. Stoel,et al.  Identifying MRI-detected inflammatory features specific for rheumatoid arthritis: two-fold feature reduction maintains predictive accuracy in clinically suspect arthralgia patients. , 2019, Seminars in arthritis and rheumatism.

[20]  D. Furst,et al.  Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study , 2019, RMD Open.

[21]  I. Auger,et al.  Porphyromonas gingivalis experimentally induces periodontis and an anti-CCP2-associated arthritis in the rat , 2019, Annals of the rheumatic diseases.

[22]  A. Zwinderman,et al.  Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study , 2018, Annals of the rheumatic diseases.

[23]  J. Yagüe,et al.  Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study , 2018, Arthritis Research & Therapy.

[24]  G. Schett,et al.  Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status , 2018, The Journal of Rheumatology.

[25]  Inge Christoffer Olsen,et al.  Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry , 2018, Rheumatology.

[26]  T. Huizinga,et al.  Triple Positivity for Anti–Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti–Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis , 2018, Arthritis & rheumatology.

[27]  Praveen Sharma,et al.  Dysbiotic Subgingival Microbial Communities in Periodontally Healthy Patients With Rheumatoid Arthritis , 2018, Arthritis & rheumatology.

[28]  A. Iagnocco,et al.  The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology Group for Ultrasound: the STARTER study , 2018, Annals of the rheumatic diseases.

[29]  M. Buch.  Defining refractory rheumatoid arthritis , 2018, Annals of the rheumatic diseases.

[30]  A. Barton,et al.  Rheumatoid arthritis , 2018, Nature Reviews Disease Primers.

[31]  F. Breedveld,et al.  Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone , 2017, RMD Open.

[32]  T. Huizinga,et al.  Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations , 2017, Therapeutic advances in musculoskeletal disease.

[33]  D. M. van der Heijde,et al.  A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis , 2017, Arthritis & rheumatology.

[34]  J. Norris,et al.  Anti–Citrullinated Protein Antibodies Are Associated With Neutrophil Extracellular Traps in the Sputum in Relatives of Rheumatoid Arthritis Patients , 2017, Arthritis & rheumatology.

[35]  C. Allaart,et al.  Brief Report: Clinical Trials Aiming to Prevent Rheumatoid Arthritis Cannot Detect Prevention Without Adequate Risk Stratification: A Trial of Methotrexate Versus Placebo in Undifferentiated Arthritis as an Example , 2017, Arthritis & rheumatology.

[36]  P. Emery,et al.  Periodontal disease and periodontal bacteria as triggers for rheumatoid arthritis. , 2017, Best practice & research. Clinical rheumatology.

[37]  M. Konig,et al.  Aggregatibacter actinomycetemcomitans–induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis , 2016, Science Translational Medicine.

[38]  M. D. de Wit,et al.  EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis , 2016, Annals of the rheumatic diseases.

[39]  G. Schett,et al.  High prevalence of tenosynovial inflammation before onset of rheumatoid arthritis and its link to progression to RA-A combined MRI/CT study. , 2016, Seminars in arthritis and rheumatism.

[40]  M. Reijnierse,et al.  Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis. , 2016, Annals of the rheumatic diseases.

[41]  C. Allaart,et al.  Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial , 2016, The Lancet.

[42]  P. Emery,et al.  Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy. , 2016, Rheumatology.

[43]  E. Naredo,et al.  Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions , 2016, Annals of the rheumatic diseases.

[44]  L. Alfredsson,et al.  Antibodies to carbamylated α-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies , 2016, Arthritis Research & Therapy.

[45]  J. Bello-Gualtero,et al.  Periodontal Disease in Individuals With a Genetic Risk of Developing Arthritis and Early Rheumatoid Arthritis: A Cross-Sectional Study. , 2016, Journal of periodontology.

[46]  N. Fuggle,et al.  Hand to Mouth: A Systematic Review and Meta-Analysis of the Association between Rheumatoid Arthritis and Periodontitis , 2016, Front. Immunol..

[47]  G. Ferraccioli,et al.  Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission , 2016, Arthritis Research & Therapy.

[48]  P. Emery,et al.  Ultrasound findings predict progression to inflammatory arthritis in anti-CCP antibody-positive patients without clinical synovitis , 2016, Annals of the rheumatic diseases.

[49]  Charles King,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[50]  P. Emery,et al.  T cell subsets: an immunological biomarker to predict progression to clinical arthritis in ACPA-positive individuals , 2015, Annals of the rheumatic diseases.

[51]  J. Castillo-Ortiz,et al.  Autoantibodies in Prediction of the Development of Rheumatoid Arthritis Among Healthy Relatives of Patients With the Disease , 2015, Arthritis & rheumatology.

[52]  P. Emery,et al.  Is localized autoimmunity the trigger for rheumatoid arthritis? Unravelling new targets for prevention. , 2015, Discovery medicine.

[53]  P. Emery,et al.  Remission in rheumatoid arthritis: is it all the same? , 2015, Expert review of clinical pharmacology.

[54]  E. Naredo,et al.  Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis. , 2015, Rheumatology.

[55]  Qiang Feng,et al.  The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment , 2015, Nature Medicine.

[56]  S. Ajeganova,et al.  Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms , 2015, Annals of the rheumatic diseases.

[57]  J. Bijlsma,et al.  Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial , 2015, BMJ : British Medical Journal.

[58]  J. Norris,et al.  Anti-carbamylated Protein Antibodies Are Present Prior to Rheumatoid Arthritis and Are Associated with Its Future Diagnosis , 2015, The Journal of Rheumatology.

[59]  P. Emery,et al.  Sustained remission with etanercept tapering in early rheumatoid arthritis. , 2014, The New England journal of medicine.

[60]  S. Proudman,et al.  Does periodontal treatment influence clinical and biochemical measures for rheumatoid arthritis? A systematic review and meta-analysis. , 2014, Seminars in arthritis and rheumatism.

[61]  R. Zubarev,et al.  Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation , 2014, Annals of the rheumatic diseases.

[62]  P. Emery,et al.  Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study , 2014, Annals of the rheumatic diseases.

[63]  P. Emery,et al.  Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial , 2014, Annals of the rheumatic diseases.

[64]  D. van Schaardenburg,et al.  Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis , 2013, Annals of the rheumatic diseases.

[65]  Inge Christoffer Olsen,et al.  Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010 , 2013, Annals of the rheumatic diseases.

[66]  J. Norris,et al.  Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. , 2013, Arthritis and rheumatism.

[67]  C. Huttenhower,et al.  Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis , 2013, eLife.

[68]  L. Barra,et al.  Anti-citrullinated protein antibodies in unaffected first-degree relatives of rheumatoid arthritis patients. , 2013, Arthritis and rheumatism.

[69]  K. Üstün,et al.  Effects of periodontal therapy on disease activity and systemic inflammation in rheumatoid arthritis patients. , 2013, Oral diseases.

[70]  Y. Ishigatsubo,et al.  Ultrasonography is a potent tool for the prediction of progressive joint destruction during clinical remission of rheumatoid arthritis , 2013, Modern rheumatology.

[71]  B. Zeng,et al.  Analysis of Fecal Lactobacillus Community Structure in Patients with Early Rheumatoid Arthritis , 2013, Current Microbiology.

[72]  D. van Schaardenburg,et al.  The type I IFN signature as a biomarker of preclinical rheumatoid arthritis , 2013, Annals of the rheumatic diseases.

[73]  D. van Schaardenburg,et al.  A prediction rule for the development of arthritis in seropositive arthralgia patients , 2012, Annals of the rheumatic diseases.

[74]  A. Viale,et al.  Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. , 2012, Arthritis and rheumatism.

[75]  G. Burmester,et al.  Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study , 2012, Annals of the rheumatic diseases.

[76]  D. Lynch,et al.  Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? , 2012, Arthritis and rheumatism.

[77]  R. Tibshirani,et al.  Autoantibody Epitope Spreading in the Pre-Clinical Phase Predicts Progression to Rheumatoid Arthritis , 2012, PloS one.

[78]  M. Weinblatt,et al.  Sustained rheumatoid arthritis remission is uncommon in clinical practice , 2012, Arthritis Research & Therapy.

[79]  J. Rocklöv,et al.  Clinical and Epidemiological Research , 2022 .

[80]  Georg Schett,et al.  Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future , 2011, Arthritis research & therapy.

[81]  P. Emery,et al.  Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments , 2011, Annals of the rheumatic diseases.

[82]  B. Dijkmans,et al.  Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase , 2010, Annals of the rheumatic diseases.

[83]  P. Emery,et al.  Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. , 2010, Rheumatology.

[84]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.

[85]  J. Drijfhout,et al.  Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis , 2010, Annals of the rheumatic diseases.

[86]  P. Emery,et al.  Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? , 2010, Annals of the rheumatic diseases.

[87]  F. Breedveld,et al.  The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis , 2010, Annals of the rheumatic diseases.

[88]  M. Dougados,et al.  Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial) , 2009, Annals of the rheumatic diseases.

[89]  D. Symmons,et al.  Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial , 2009, Annals of the rheumatic diseases.

[90]  R. Caporali,et al.  Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. , 2009, Rheumatology.

[91]  C. Roux,et al.  Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. , 2009, Joint, bone, spine : revue du rhumatisme.

[92]  B. Dijkmans,et al.  Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study , 2009, Annals of the rheumatic diseases.

[93]  B. Dijkmans,et al.  Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial , 2009, Annals of the rheumatic diseases.

[94]  C. Peterfy,et al.  An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[95]  F. Breedveld,et al.  Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial , 2008, The Lancet.

[96]  P. Toivanen,et al.  Fecal microbiota in early rheumatoid arthritis. , 2008, The Journal of rheumatology.

[97]  L. Klareskog,et al.  Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells , 2008, Annals of the rheumatic diseases.

[98]  Sarah L. Field,et al.  Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse , 2007, Annals of the rheumatic diseases.

[99]  J. Smolen,et al.  Assessing remission in clinical practice. , 2007, Rheumatology.

[100]  C. Allaart,et al.  Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. , 2007, Arthritis and rheumatism.

[101]  C. Peterfy,et al.  Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. , 2006, Arthritis and rheumatism.

[102]  B. Dijkmans,et al.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. , 2005, Arthritis and rheumatism.

[103]  B. Dijkmans,et al.  Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. , 2004, Arthritis and rheumatism.

[104]  Göran Hallmans,et al.  Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[105]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[106]  L. Alfredsson,et al.  A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. , 2006, Arthritis and rheumatism.

[107]  Alexander Fraser,et al.  Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-contro , 2005, Arthritis and rheumatism.

[108]  Maarten Boers,et al.  Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. , 2004, Arthritis and rheumatism.